.jpeg)
2026-01-19 06:07:42
Pralsetinib is a revolutionary high-selectivity RET inhibitor, precisely designed for the treatment of lung and thyroid cancers harboring RET gene mutations. With superior efficacy compared to traditional therapies and enhanced safety profile, it has delivered breakthrough survival benefits for patients with these rare mutations, establishing itself as the new standard of care.
2026-01-15 06:18:33
On October 24,2025,Syndax Pharmaceuticals announced that the U.S.Food and Drug Administration(FDA)has approved Revuforj(revumenib)for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory(R/R)acute myeloid leukemia(AML)carrying nucleolar phosphoprotein 1(NPM1)mutations and for whom there are no suitable alternative treatment options.Revuforj was previously approved in 2024 for the treatment of adult and pediatric patients aged 1 year and older with R/R acute leukemia associated with a lysine methyltransferase 2A gene(KMT2A)translocation.
2026-01-15 05:54:14
Celecoxib is a selective COX-2 inhibitor that exerts anti-inflammatory and analgesic effects to relieve the symptoms of cervical spondylosis (such as radiculopathy type and cervical type).
